Search
Rimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigationalsafer for use in patients with contraindications to standard therapy. … Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals.
Triclabendazole
go.drugbank.com/drugs/DB12245ApprovedInvestigationalTriclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans. … Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use.
Teduglutide
go.drugbank.com/drugs/DB08900ApprovedInvestigationalFDA approved on December 21, 2012.
Categories: Compounds used in a research, industrial, or household settingScarlet red
go.drugbank.com/drugs/DB19136ApprovedWithdrawnScarlet red is under investigation in clinical trial NCT00591916 (New Treatment for Donor Sites).
Categories: Compounds used in a research, industrial, or household settingAlternaria alternata
go.drugbank.com/drugs/DB10424ApprovedAlternaria alternata extract is used in allergenic testing.
Mixtures: Number Ten Mold Mixture, Number Ten Mold MixtureCollagenase clostridium histolyticum
go.drugbank.com/drugs/DB00048ApprovedInvestigational[L14912] On July 6, 2020 a combination of injectable bacterial collagenases was approved by the FDA for the treatment of cellulite in adult women. … Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum.
Parachlorophenol
go.drugbank.com/drugs/DB13154ApprovedWithdrawnSlightly soluble to soluble in water, depending on the isomer, and denser than water. Noncombustible.
Sotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigational[A187547] Sotorasib was granted FDA approval on May 28, 2021,[L34288] followed by the European Commission's approval on January 6, 2022.[L56070] … Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen.
Trametinib
go.drugbank.com/drugs/DB08911ApprovedInvestigational[A258298] It was later approved by Health Canada on July 18, 2013 [L45588] and by the European Commission on June 30, 2014. … [A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma.
Doravirine
go.drugbank.com/drugs/DB12301ApprovedInvestigationalDoravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines. … [L4562] Doravirine is formally indicated for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment experience, further expanding the possibility and choice of therapeutic
Categories: Antivirals used in combination for the treatment of HIV infections